Related Experiment Video
Updated: Nov 30, 2025
Autonomous and Rechargeable Microneurostimulator Endoscopically Implantable into the Submucosa
Published on: September 27, 2018
[Sacral electrical neurostimulation in the refractory pediatric overactive bladder]
I Casal-Beloy1, M A García-Novoa, T Casal Beloy
1Servicio de Cirugía Pediátrica. Complejo Hospitalario Universitario A Coruña. La Coruña. España.. isabelcasalbe@gmail.com.
Insights
Sacral vesical electrotherapy effectively treated a 12-year-old with refractory overactive bladder. This approach resolved symptoms of diurnal incontinence and urgency without adverse effects, offering a new option for difficult cases.
Area of Science:
- Pediatric Urology
- Neuromodulation
- Bladder Dysfunction
Background:
- Overactive bladder (OAB) is a common cause of pediatric urinary incontinence.
- Current treatments like oxybutynin have limited efficacy for some patients.
- Anticholinergic refractory OAB requires alternative management strategies.
Observation:
- A 12-year-old patient presented with refractory OAB symptoms including diurnal incontinence and urgency.
- The patient had previously failed treatment with oxybutynin and solifenacin.
- Sacral vesical electrotherapy was considered as a novel treatment option.
Findings:
- Sacral vesical electrotherapy led to a complete resolution of diurnal incontinence and urgency.
- The patient experienced no adverse effects during or after the electrotherapy treatment.
- This case demonstrates a positive response to sacral vesical electrotherapy in a pediatric OAB patient.
Implications:
- Sacral vesical electrotherapy shows promise as an effective treatment for pediatric OAB refractory to oral medications.
- This intervention may offer a safe and viable alternative for managing complex bladder dysfunction in children.
- Further research is warranted to establish the long-term efficacy and broader applicability of vesical electrotherapy in pediatric urology.
Abstract:
Urinary incontinence is one of the principal reasons for visiting the urologist amongst paediatric patients, and an overactive bladder is the vesical dysfunction that most frequently provokes this. Currently the only medicine approved for managing an overactive bladder is oxybutynin; however, many patients respond partially to this therapy or are refractory to it. Vesical electrotherapy has emerged as a new alternative in the algorithm for managing patients with an overactive bladder refractory to anticholinergic medicines, but the evidence on this issue has to date been scant. We present the case of a 12-year-old patient with an overactive bladder refractory to oxybutynin and solifenacin who presented a good response to treatment with sacral vesical electrotherapy, with complete disappearance of the symptoms (diurnal incontinence and urgency of micturition) without adverse effects.
